HealthMore in Health→
CRISPR-Edited Bone Marrow Transplant Strategy Shows Early Promise in High-Risk AML
Key Takeaways
- A phase 1/2a trial tested a CRISPR-edited allogeneic transplant product lacking CD33 in high-risk AML and MDS.
- All 30 treated patients achieved neutrophil engraftment by day 28, with a median time of 10 days.
- Nineteen patients received gemtuzumab ozogamicin maintenance, which was tolerated up to the recommended phase 2 dose.
DE
DT Editorial Team··via nature.com